EDISON, N.J., Dec. 15 The Musculoskeletal TransplantFoundation (MTF) announced today that it has completed a major portion of thedevelopment phase in its efforts to develop a next-generation stem cellallograft tissue form in partnership with Orthofix International N.V. (Nasdaq:OFIX). MTF's research team has delivered a robust data package to Orthofixwhich confirms the relative superiority of this tissue form against othersimilar tissue forms already on the market. The partnership between MTF andOrthofix has now achieved success in the development phase, allowing the quicktransition to commercialization and an expectation that the tissue form willbe available to surgeons by June 2009.
"Our partnership with Orthofix is an excellent example of how thenon-profit and for-profit worlds can work together to pursue medical advancesthat will significantly benefit patients," said Bruce Stroever, CEO of MTF."Our team is very pleased to have achieved this major development milestone,knowing that it means surgeons will have a next-generation stem cell-basedallograft available for use within six months."
In 2008, MTF and Orthofix announced a Development Agreement to worktogether to develop and distribute a stem cell-based allograft tissue form.The new tissue form, called Trinity Evolution(TM), will bring advances to thesurgical use of allografts. The tissue form is a stem cell-based bone growthmatrix designed to behave like an autograft in spinal and orthopedicsurgeries.
In addition to its research and development expertise, MTF acts as abridge between the donor, the donor family and the transplant recipient;processing and distributing allograft tissue to hospitals and clinics aroundthe country. As a non-profit service organization, MTF provides quality tissuethrough a commitment to excellence in education, research, recovery and carefor recipients, donors and their families.
"The Musculoskeletal Transplant Foundation is a world leader in tissueresearch and development, and we knew that together we could make greatadvances in medical science," said Alan Milinazzo, CEO of Orthofix. "Thecommercialization of Trinity Evolution(TM) will provide surgeons and theirpatients with an exciting new stem cell-based tissue form for use in surgicalbone grafting procedures."
With the completion of this major development milestone, MTF will now turnits focus to producing the allograft and preparing for a commercial launchwith Orthofix by June of 2009.
About The Musculoskeletal Transplant Foundation
The Musculoskeletal Transplant Foundation is the nation's largest fullservice tissue organization dedicated to providing quality tissue through acommitment to excellence in education, research, recovery and care forrecipients, donors and their families. A not-for-profit organization, MTF is aconsortium of academic medical institutions and organ and tissue recoveryorganizations across the country. In its first 20 years, MTF and its recoverypartners have recovered over 60,000 donors and provided over three milliontissue grafts to patients in need. For more information, please visit MTF'swebsite at www.mtf.org.
Orthofix International N.V., a global diversified orthopedic productscompany, offers a broad line of minimally invasive surgical, and non-surgical,products for the spine, orthopedic, and sports medicine market sectors thataddress the lifelong bone and joint health needs of patients of all ages,helping them achieve a more active and mobile lifestyle. Orthofix's productsare widely distributed around the world to orthopedic surgeons and patientsvia Orthofix's sales representatives and its subsidiaries, including BREG,Inc. and Blackstone Medical, Inc., and via partnerships with other leadingorthopedic product companies. In addition, Orthofix is collaborating in R&Dpartnerships with leading medical institutions such as the Orthopedic Researchand Education Foundation, Rutgers University, the Cleveland Clinic Foundation,Texas Scottish Rite Hospital for Children and National Osteoporosis Institute.For more information about Orthofix, please visit www.orthofix.com.
SOURCE Musculoskeletal Transplant Foundation